Intraoperative clonidine in endometriosis and spine surgery: A protocol for two randomised, blinded, placebo-controlled trials.
Autor: | Birkebæk S; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Lundsgaard LM; Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark., Juul N; Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark., Seyer-Hansen M; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Gynaecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark., Rasmussen MM; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark., Uhrbrand PG; Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark., Nikolajsen L; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark. |
---|---|
Jazyk: | angličtina |
Zdroj: | Acta anaesthesiologica Scandinavica [Acta Anaesthesiol Scand] 2024 May; Vol. 68 (5), pp. 708-713. Date of Electronic Publication: 2024 Mar 10. |
DOI: | 10.1111/aas.14398 |
Abstrakt: | Background: A high proportion of patients who undergo surgery continue to suffer from moderate to severe pain in the early postoperative period despite advances in pain management strategies. Previous studies suggest that clonidine, an alpha Aim: To investigate the effect of a single intravenous (IV) dose of intraoperative clonidine on postoperative opioid consumption, pain intensity, nausea, vomiting and sedation after endometriosis and spine surgery. Methods: Two separate randomised, blinded, placebo-controlled trials are planned. Patients scheduled for endometriosis (CLONIPAIN) will be randomised to receive either 150 μg intraoperative IV clonidine or placebo (isotonic saline). Patients undergoing spine surgery (CLONISPINE) will receive 3 μg/kg intraoperative IV clonidine or placebo. We aim to include 120 patients in each trial to achieve power of 90% at an alpha level of 0.05. Outcomes: The primary outcome is opioid consumption within the first three postoperative hours. Secondary outcomes include pain intensity at rest and during coughing, nausea, vomiting and sedation within the first two postoperative hours and opioid consumption within the first six postoperative hours. Time to discharge from the PACU will be registered. Conclusion: This study is expected to provide valuable information on the efficacy of intraoperative clonidine in acute postoperative pain management in patients undergoing endometriosis and spine surgery. (© 2024 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.) |
Databáze: | MEDLINE |
Externí odkaz: |